Custom lipid nanoparticle formulation and optimization services for stable, efficient, and application-driven circRNA delivery.
Circular RNA (circRNA) is attracting increasing interest in RNA therapeutics research because its covalently closed structure can support enhanced nuclease resistance, prolonged intracellular persistence, and sustained protein expression compared with many linear RNA formats. However, successful circRNA delivery requires more than simply adapting an mRNA-LNP protocol. The larger hydrodynamic behavior of circRNA constructs, circularization-related impurities, sequence-dependent folding, translation element design, and lipid-cargo interactions can all affect encapsulation, particle morphology, endosomal escape, cellular uptake, and downstream expression. BOC Sciences provides specialized lipid nanoparticle services for circRNA delivery, supporting formulation screening, lipid composition optimization, encapsulation assessment, physicochemical characterization, stability evaluation, and in vitro performance studies. Our goal is to help research teams transform circRNA constructs into robust LNP formulations with clear structure-performance relationships and reliable data for internal R&D decision-making.
LNP lipid shell and circRNA coreWe provide an integrated service framework for developing lipid nanoparticles tailored to circular RNA cargo. Each project is designed around the circRNA sequence, length, translation architecture, target cell type, intended experimental model, and required performance readouts, rather than relying on a generic nucleic acid formulation recipe.
We design and screen lipid nanoparticle formulations to balance circRNA encapsulation, colloidal stability, cellular delivery, and protein expression. Formulation variables are selected according to cargo length, buffer compatibility, RNA concentration, and intended biological application.
Because circRNA topology and purification profile can influence lipid complexation, encapsulation optimization must distinguish truly entrapped RNA from surface-associated or free circRNA. BOC Sciences supports lipid nanoparticle encapsulation development with cargo-specific analytical strategies.
Ionizable lipid chemistry is a key determinant of circRNA complexation, endosomal escape, intracellular release, and tolerability in biological models. We provide targeted screening strategies through LNP ionizable lipid optimization services to identify lipid compositions suited to circRNA delivery.
CircRNA-LNP performance is strongly influenced by mixing kinetics. BOC Sciences supports controlled, reproducible particle assembly through microfluidic LNP production services, enabling systematic comparison of formulation and process variables.
For research programs requiring cell- or tissue-preferential delivery, we support formulation strategies that combine passive biodistribution tuning with ligand-functionalized LNP design. Our targeted LNP development capabilities help improve the match between circRNA cargo, target cell biology, and delivery route.
High uptake does not always produce high circRNA expression. We evaluate whether formulation bottlenecks arise from insufficient endosomal escape, poor intracellular release, RNA degradation, translation element inefficiency, or excessive particle-cell interaction.
circRNA delivery differs from conventional linear RNA delivery in cargo topology, translation mechanism, impurity sensitivity, and formulation response. We combine lipid nanoparticle engineering with RNA-aware analytical design to establish practical optimization logic for each project.
From lipid screening and microfluidic assembly to encapsulation analysis and expression troubleshooting, BOC Sciences helps convert circRNA concepts into optimized delivery systems.
BOC Sciences supports a broad range of circular RNA constructs and lipid nanoparticle formats. Our team customizes formulation design, preparation parameters, purification strategy, and analytical readouts according to the physical properties of the circRNA and the biological objective of the delivery study.
| circRNA-LNP System | Service Focus and Typical Research Use |
|---|---|
| Lipid Nanoparticles for circRNA Delivery | General circRNA encapsulation, particle assembly, physicochemical characterization, and expression testing for reporter or protein-coding circRNA constructs. |
| Ionizable circRNA-LNPs | pH-responsive formulations designed to enhance endosomal escape and cytosolic release while maintaining low surface charge at neutral pH. |
| PEGylated circRNA-LNPs | Formulations with controlled PEG-lipid content to regulate particle size, aggregation, storage stability, and biological interaction. |
| Ligand-Functionalized circRNA-LNPs | Peptide-, antibody-, sugar-, or small molecule-modified systems for receptor-associated uptake studies and cell-preferential delivery exploration. |
| Reporter circRNA-LNPs | Luciferase, GFP, mCherry, or secreted reporter constructs used to compare formulation variables, delivery routes, and expression kinetics. |
| Protein-Coding circRNA-LNPs | Delivery systems for sustained expression of therapeutic proteins, enzymes, cytokine-related research proteins, or antigenic proteins in discovery-stage studies. |
| Immune-Cell-Oriented circRNA-LNPs | Formulations designed for dendritic cell, macrophage, or lymphoid-cell delivery research, with attention to uptake, expression, and innate response profiling. |
| Organ-Targeted circRNA-LNPs | Liver-, lung-, tumor-, or brain-oriented LNP development strategies for biodistribution and expression studies in suitable experimental models. |
circRNA delivery programs often encounter bottlenecks that are not visible from encapsulation efficiency alone. We help identify the formulation, analytical, and biological factors limiting delivery performance.
✔ Low circRNA Encapsulation
Large or highly structured circRNA constructs may show reduced complexation during rapid mixing. We adjust N/P ratio, buffer pH, RNA input concentration, lipid concentration, and mixing parameters to improve encapsulation without increasing particle heterogeneity.
✔ Large Particle Size or Broad PDI
Oversized circRNA-LNPs can result from slow mixing, lipid precipitation, RNA aggregation, or excessive cargo loading. We use formulation mapping and process optimization to reduce PDI and stabilize nanoscale particle populations.
✔ High Uptake but Weak Expression
Cellular internalization does not guarantee functional cytosolic delivery. We combine uptake assays with LNP endosomal escape evaluation to determine whether expression is limited by intracellular release.
✔ circRNA Integrity Loss
Mechanical stress, residual nuclease activity, inappropriate buffer conditions, or excessive purification exposure can compromise circRNA integrity. We design gentle workflows and monitor RNA recovery after formulation and purification.
✔ Unclear Structure-Performance Relationship
Similar encapsulation values may produce very different expression profiles. We integrate particle size, surface charge, morphology, encapsulation, uptake, endosomal escape, and expression kinetics to reveal the true performance drivers.
✔ Poor Storage or Freeze-Thaw Stability
circRNA-LNPs may aggregate, leak cargo, or lose expression after storage. We evaluate buffer systems, cryoprotectants, temperature exposure, and freeze-thaw cycles through lipid nanoparticle stability studies.
We review circRNA length, sequence architecture, translation element, buffer composition, target cell model, and desired readouts to define the formulation strategy and analytical plan.
Candidate formulations are prepared using controlled mixing conditions. Lipid ratios, N/P ratio, flow parameters, buffer pH, and purification options are screened to identify promising circRNA-LNP systems.
We measure particle size, PDI, zeta potential, encapsulation efficiency, morphology, RNA integrity, and expression performance. Additional lipid nanoparticle characterization can be integrated when deeper formulation insight is required.
Results are interpreted across formulation variables to identify the best-performing compositions and recommend next-step optimization for encapsulation, stability, uptake, endosomal escape, or expression.
Challenge: A research group provided a 3.2 kb luciferase circRNA construct that showed acceptable apparent encapsulation but weak protein expression in HEK293T and hepatocyte-like cells. Initial particles had an average diameter above 180 nm, PDI around 0.28, and inconsistent expression across repeated preparations.
Diagnosis: BOC Sciences compared total circRNA recovery, dye-accessibility-based encapsulation, particle size distribution, and expression kinetics. The data indicated that high RNA input caused heterogeneous particles and that a fraction of circRNA was surface-associated rather than fully protected. Confocal imaging further suggested strong endosomal retention despite visible cellular uptake.
Solution: We screened six lipid compositions by adjusting ionizable lipid content, DOPE/DSPC helper lipid balance, cholesterol ratio, and PEG-lipid percentage. Microfluidic conditions were then optimized by testing three flow rate ratios and two aqueous buffer pH values. The best formulation reduced mean particle size to approximately 95-115 nm, lowered PDI below 0.18, and improved protected circRNA fraction after nuclease challenge. A DOPE-enriched helper lipid design was selected because it produced stronger expression without increasing aggregation after 24-hour storage at 4 °C.
Result: The optimized circRNA-LNP increased luciferase signal by more than 5-fold compared with the starting formulation in in vitro expression assays, while maintaining a narrower particle distribution and improved circRNA protection.
Challenge: A discovery-stage team needed a circRNA-LNP formulation for dendritic-cell delivery research. Their original PEGylated LNP showed stable particle size but low uptake in DC2.4 cells and limited expression of a model antigen-coding circRNA.
Diagnosis: We evaluated PEG-lipid molar percentage, ligand accessibility, uptake efficiency, and expression output. The original formulation had a low aggregation profile but excessive surface shielding, limiting cell interaction. Reducing PEG-lipid alone improved uptake but increased particle instability, indicating that ligand display and colloidal balance needed to be optimized together.
Solution: BOC Sciences prepared a small formulation matrix combining reduced PEG-lipid content, mannose-bearing lipid incorporation, and two ionizable lipid candidates with different pH-responsive profiles. We compared particle size, PDI, encapsulation efficiency, serum-containing medium stability, receptor-associated uptake, and antigen-expression kinetics. The selected formulation used a moderate mannose-lipid density and an ionizable lipid that supported stronger endosomal release, achieving a particle size near 120 nm and PDI below 0.20 after purification.
Result: The optimized targeted circRNA-LNP produced approximately 3.8-fold higher antigen expression than the non-targeted control in dendritic-cell assays, while preserving acceptable colloidal stability during short-term handling.
circRNA-Specific Formulation LogicWe account for circRNA topology, construct length, translation element, impurity profile, and structural behavior instead of treating circular RNA as a direct substitute for linear mRNA.
Integrated LNP DevelopmentOur capabilities cover lipid selection, lipid nanoparticle formulation, microfluidic preparation, purification, and performance-oriented optimization in one coordinated workflow.
Mechanistic TroubleshootingWe distinguish between uptake failure, endosomal escape limitation, circRNA instability, surface adsorption, and translation inefficiency to provide actionable optimization directions.
Broad Analytical SupportParticle size, zeta potential, morphology, encapsulation, RNA integrity, storage stability, cellular uptake, and expression readouts can be integrated to build a complete formulation-performance profile.
Flexible Targeting StrategiesWe support ligand-functionalized and organ-oriented circRNA-LNP development, including peptide-, antibody-, sugar-, and small molecule-guided delivery designs for research applications.
Lipid nanoparticles help protect circRNA from nuclease degradation, improve cellular uptake, and support intracellular release after endocytosis. Compared with naked circRNA, LNP-encapsulated circRNA can achieve better colloidal stability, reduced premature degradation, and more controllable delivery behavior. For drug discovery teams, the key value of LNPs is not only cargo protection, but also formulation tunability. By adjusting ionizable lipids, helper lipids, cholesterol, PEG-lipids, N/P ratio, buffer conditions, and particle size distribution, researchers can optimize encapsulation, transfection efficiency, and expression duration for different cell types and application models.
circRNA encapsulation efficiency is influenced by RNA length, circularization quality, secondary structure, lipid composition, aqueous-to-organic phase ratio, flow rate, mixing speed, N/P ratio, pH, ionic strength, and post-formulation processing conditions. circRNA molecules are often larger and structurally more complex than short oligonucleotides, so formulation conditions must be carefully optimized to avoid incomplete encapsulation, aggregation, or reduced translation performance. BOC Sciences can support systematic formulation screening by comparing lipid ratios, ionizable lipid structures, buffer systems, and microfluidic mixing parameters to identify LNP compositions that balance encapsulation efficiency, particle uniformity, and functional protein expression.
circRNA delivery is challenging because circRNA is a large, negatively charged, structurally complex nucleic acid that cannot efficiently cross cell membranes on its own. It is also sensitive to process-related stress, nuclease exposure, and unfavorable formulation microenvironments. Even when circRNA is successfully encapsulated, delivery performance may still be limited by particle instability, poor cellular uptake, endosomal trapping, inefficient cytoplasmic release, or reduced translation activity. A successful LNP-circRNA system therefore requires coordinated optimization of RNA quality, lipid composition, particle size, surface properties, encapsulation conditions, and functional readouts rather than relying on a single formulation parameter.
LNP-circRNA formulations should be evaluated through both physicochemical and functional assays. Common characterization items include particle size, polydispersity index, zeta potential, encapsulation efficiency, RNA integrity, morphology, colloidal stability, serum stability, and storage stability under selected conditions. Functional evaluation may include cellular uptake, reporter protein expression, expression duration, cytotoxicity, and comparison across relevant cell models. For formulation development, it is important to connect analytical data with biological performance. A formulation with high encapsulation efficiency is not necessarily the best candidate if it shows poor endosomal escape or weak protein expression, so multi-parameter assessment is essential.
Yes. LNP systems can be customized according to circRNA size, target cell type, intended expression profile, route of administration for research models, and downstream evaluation needs. For example, one project may prioritize high protein expression in immune cells, while another may require improved stability for a long circRNA encoding a large protein. Customization may involve screening ionizable lipids, adjusting helper lipid and cholesterol ratios, tuning PEG-lipid content, modifying particle size, or comparing buffer and mixing conditions. BOC Sciences provides formulation development and characterization support to help researchers establish LNP-circRNA systems that are better aligned with specific experimental goals.
